Cargando…

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis

BACKGROUND: For patients with rheumatoid arthritis (RA) who discontinued initial treatment with tumor necrosis factor inhibitor (TNFi), 2 approaches are commonly used: cycling to another TNFi or switching to a drug with another mechanism of action. Currently, there is no consensus on which approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karpes Matusevich, Aliza R, Lal, Lincy S, Chan, Wenyaw, Swint, J Michael, Cantor, Scott B, Suarez-Almazor, Maria E, Lopez-Olivo, Maria A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391179/ https://www.ncbi.nlm.nih.gov/pubmed/33377443 http://dx.doi.org/10.18553/jmcp.2021.27.1.073

Ejemplares similares

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis
por: Sonawane, Kalyani, et al.
Publicado: (2020)

Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis
por: Pan, Xin, et al.
Publicado: (2017)

Shorter length of hospital stay for hip fracture in those with dementia and without a known diagnosis of osteoporosis in the USA
por: Rasu, Rafia S., et al.
Publicado: (2020)

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
por: Uhrenholt, Line, et al.
Publicado: (2019)

A systematic review with meta-analysis of the effects of smoking cessation strategies in patients with rheumatoid arthritis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2016)

Evaluation of a Virtual Networking Event for Emerging Women Leaders in Global Health
por: Iyengar, Sloka, et al.
Publicado: (2022)

Correction: Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis—A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2017)

Pharmacotherapy Options in Rheumatoid Arthritis
por: Kumar, Pradeep, et al.
Publicado: (2013)

Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach
por: Mahlich, Jörg, et al.
Publicado: (2019)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
por: Michaud, Kaleb, et al.
Publicado: (2019)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis
por: Park, Siyeon, et al.
Publicado: (2019)

Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
por: Köhler, Birgit M., et al.
Publicado: (2019)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Use of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Supporting Shared Decision‐Making Between Patients With Cancer and Clinicians
por: Singh, Namrata, et al.
Publicado: (2023)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis
por: Sato, Tomohito, et al.
Publicado: (2014)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
por: Lin, Yen-Ju, et al.
Publicado: (2020)

Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options
por: Pavlov-Dolijanovic, Slavica, et al.
Publicado: (2023)

Informal science, technology, engineering and math learning conditions to increase parent involvement with young children experiencing poverty
por: Zucker, Tricia A., et al.
Publicado: (2022)

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register
por: McWilliams, Daniel F., et al.
Publicado: (2016)

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review
por: Ruiz, Juan I., et al.
Publicado: (2023)

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
por: Bolge, Susan C, et al.
Publicado: (2015)

Comparison of Biologic Discontinuation in Patients With Elderly‐Onset Versus Younger‐Onset Rheumatoid Arthritis
por: Richter, Michael D., et al.
Publicado: (2019)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
por: Perpétuo, Inês P., et al.
Publicado: (2017)

Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study
por: Jinno, Sadao, et al.
Publicado: (2021)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2015)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5cs5bv1b02gme82u35m7o8quig